1

National Reports

2

Standard Table 10

3

Structured Questionnaire 23

4

Estimated value

5

Personal communication H Stöver 31.01.05

6

Personal communication M Camilleri 14.02.05

7

Coutinho R (1995) Am J Public Health 85, 1490-1

8

The sale of syringes without prescription is not legal in Sweden.

9

Circulaire DGS 05 May 1992 already allows a pilot study of NSPs, but full implementation only 1995.

10

Personal communication E Subata 28.02.05

11

Pharmaceutical Group of the European Union (www.pgeu.org)

12

Associação Nacional de Farmácias (www.anf.pt)

13

Study on pharmacy syringe sales: Zábranský, T., Radimecký, J., Mravčík, V., Gajdošíková, H., Petroš, O., Korčišová, B., Miovský, M., Vopravil, J., Csémy, L. and Kuda, A.a.N. (2002) Výroční zpráva o stavu ve věcech drog v ČR v r. 2001. Praha (Prague): Úřad vlády ČR. & National Report Czech Republic 2002

14

www.statistics.gov.uk

15

www.parliament.the-stationery-office.co.uk

16

National Public Health Service for Wales/Royal Pharmaceutical Society of Great Britain; data refer to number of needles. Reference period: fiscal year 2002/2003.

17

Northern Ireland Needle and Syringe Exchange Database

18

Personal communication B Korcisova 09.03.05

19

NSPs exist in Sofia, Burgass, Plovdiv, Pernik, Blagoevgrad, Kustendil, Pazardgik, Ruse, Varna.

20

Excluding Stérikit sales

21

Emmanuelli, J. (2003), Siamois: Tendances en matière de réduction des risques chez les usagers de drogues par voie iv, In: Bello, J-Y., Toufik, A., Gandilhon, M., Giraudoin, I. and Bonnet, N., Phénomènes émergents liés aux drogues en 2002, quatrième rapport national du dispositif TREND, Paris, OFDT, pp 263-267.

22

Malin, K., Holmström, P., Holopainen, A., Partanen, A., (2004), Huumeidenkäyttäjät apteekkien asiakkaina vuosina 2001 ja 2003, A-klinikkasäätiön monistesarja nro 43. Ilmestyy loppuvuonna 2004.

23

www.mainline.org

24

Data from the United Kingdom refer to the fiscal year (March to February).

25

Provisional results of national audit of needle exchange, reference period fiscal year 2003/2004, e-mail communication David Best, Head of Research, National Treatment Agency, 13 July 2005